

Interim Report FY25



Contents

| Highlights | 1 |
|--|----|
| Chair and Managing Directors' Reports | 2 |
| GAAP to Non-GAAP Reconciliation | 5 |
| Consolidated Condensed Interim Financial Statements | 6 |
| Notes to the Consolidated Condensed Interim Financial Statements | 14 |
| Directory | 21 |
| | |

Highlights

For the six months ended 31 March 2025

Sales revenue

HY25:

\$286.0m

HY24: \$276.0m

1

4%

Gross margin %

HY25:

28.2%

HY24: 24.9%

13%

4.9%

Adjusted EBIT

HY25:

\$54.0m

HY24: \$38.5m

1

40%

Net profit after tax (NPAT)

HY25:

\$34.0m

110%

HY24: \$16.2m

Operating cash flow

HY25:

\$49.6m

HY24: \$8.3m

1

498%

Net debt

HY25:

\$165.1m

HY24: \$220.5m

25%

Earnings per share

HY25:

36.4 cps

HY24: 17.3 cps

1

110%

Interim dividend

HY25:

5.0 cps

HY24: 5.0 cps



Chair and Managing Directors' Reports

Managing Director's Report

I am pleased to report to Sanford Shareholders after being Managing Director (MD) for a little over 12 months.

I approached my first year with a particular focus on operating cashflow, debt reduction, business simplification and cost rationalisation. There is still a long way to go but we have made a good start, and I believe there are many more opportunities for improvement.

Sanford's interim financial results represent a record profit for the company. Revenue of \$286.0m was only 4% up on the prior comparative period (pcp). However, net profit after tax (NPAT) at \$34.0m was a pleasing 110% up over the prior period. Operating cashflow of \$49.6m is a \$41.3m (498%) improvement on pcp. Net debt has dropped to \$165.1m from \$220.5m in March 2024, a \$55.4m decrease.

We are now focused on operating as a commodity player, where reducing costs and operating more efficiently is critical for success. Overheads are coming down and debt has dropped to more reasonable levels, albeit in my view still too high. Driving product costs down and lowering overheads will make us more competitive in any market.

The salmon business has been a standout for the first half with revenue and contribution up 24% and 32% respectively. We made a conscious effort to bring sales forward to reduce stock in water during the higher risk summer months and to maximise returns due to future tariff uncertainty.

This decision proved successful and highlighted the market potential to absorb more volume while maintaining price. Salmon has limited volume growth opportunities without significant investment. However, I believe there are many opportunities to improve profitability by incrementally improving our processing and farming operations.

Our mussel business had a significant improvement in profitability with contribution lifting by 97%. Prices and demand have remained positive, and the business has been taking out costs and eliminating inefficiencies where possible (such as the exit of the of Tauranga processing site). Unlike salmon, the mussel business does have opportunities to grow at lower cost due to unused waterspace that is not currently being farmed. Further work is required in this area.


Wildcatch profitability was 10% down on pcp. This is mostly related to reduced scampi sales, and the timing of squid catch. Our current success in this business is very much tied to scampi and commodity white fish such as hoki and orange roughy. We are at the mercy of global prices, that are currently under pressure. Deepwater fishing is very capital intensive with the costs of maintaining an effective fleet expensive. This is an industry wide issue, and I will be considering all options with a focused review in the next 12 months. The exit out of the inshore fishery and closure of our Auckland factory has been positive for our bottom line while maintaining ownership of our quota assets.


Capital Allocation

We are now focused on a more disciplined capital investment process, and a review of assets has shown some opportunities for rationalisation and even disposal that improves our cash (and debt) position.

The two charts below highlight achievements in terms of decreasing debt and reducing interest costs over the last 12 months. My intention is to reduce debt further by year-end that will put the company on a more solid platform to take advantage of investment opportunities should they arise.







Strategic Review

Turbulence in markets has required a change in focus to first considering key customers in key markets. Sanford has become concentrated on several markets, in particular the US and China. Clearly, this front-end activity will require a lot more time going forward.

Our sales team (front end) have done a very good job of rationalising finished goods stock keeping units (skus) and reviewing pricing leading to small but important improvements in margin. They have continued selling through inventory and converting to cash.

We have managed to review most of the growth and associated capital plans for our Aquaculture (Salmon and Mussels) business. This included a deep review of assets. We are confident that we can improve performance at a lower capital spend.

Obviously, the next area of focus is wildcatch where our immediate focus is on catching and selling scampi.

Sustainability

In January 2025, Sanford issued its first stand-alone sustainability report. Operating in a sustainable industry is very important for us and understanding the potential impact of climate change on New Zealand wildfish and aquaculture is critical for our success. We have invested in additional resource to support our understanding of climate related impacts and help develop mitigation strategies for the company.

Our People

There has been significant change in the business since I last reported to shareholders and this inevitability impacts people. The senior executive team have been trimmed down and changes have been made with fewer people required.

I would like to thank staff for their efforts during this period of uncertainty and change.

I would also like to thank our directors and shareholders for their support.

Chair's Report New Leadership

The Board is very pleased with Sanford's half year financial performance to 31 March 2025, and the Board particularly thanks our management team and people led by David for a job well done. Our internal management results and our external share price have both improved during this reporting period, which is an important goal of the business. I reiterate David's comments that much change has been implemented with still more to be done. You will see that most of the effort and result has been on reducing costs and debt. This has strengthened Sanford's balance sheet enabling the company to be more resilient in tougher times but more responsive to opportunities as they arise. Consistent with this strategy, the Board continues to take a conservative approach to dividend policy and accordingly recommends an interim dividend of 5.0c per share.

The first-half result is positive, however we do not anticipate the same level of profitability in the second half due to in-market price pressures and seasonal volume fluctuations.

r Robert McLeod David Mair

Sir Robert McLeod Chairman David Mair Managing Director

GAAP to Non-GAAP Reconciliation

| | 6 months ended 31 March 2025 | 6 months ended 31 March 2024 | 12 months ended 30 September 2024 |
|--|---------------------------------|---------------------------------|--------------------------------------|
| | \$000 | \$000 | \$000 |
| Reported net profit for the period (GAAP) | 34,033 | 16,154 | 19,670 |
| Add back: | | | |
| Income tax expense | 13,518 | 9,833 | 17,725 |
| Net interest expense | 6,906 | 9,200 | 16,867 |
| EBIT | 54,457 | 35,187 | 54,262 |
| Adjustments: | | | |
| Restructuring costs | 408 | 659 | 1,495 |
| Impairment of assets | 115 | _ | 16,856 |
| Net loss on sale of property, plant and equipment and intangibles | 63 | 6 | 293 |
| Gain on sale of North Island Mussels Limited assets | (1,040) | _ | _ |
| Net gain on sale of North Island inshore fishery assets | _ | (964) | (964) |
| Impairment of investment and advances in Two Islands Co NZ Limited | _ | 3,333 | 3,132 |
| Other one-off losses/(gains) | _ | 257 | (866) |
| Adjusted EBIT | 54,003 | 38,478 | 74,208 |
| Add back: | | | |
| Depreciation and amortisation | 17,393 | 17,542 | 34,442 |
| Adjusted EBITDA | 71,396 | 56,020 | 108,650 |

GAAP to Non-GAAP Reconciliation

Sanford's standard profit measure prepared under New Zealand GAAP is net profit. Sanford has used non-GAAP measures when discussing financial performance. The Directors and management believe that these measures provide useful information as they are used internally to evaluate business unit and total Group performance and to establish operating and capital budgets. Non-GAAP profit measures are not prepared in accordance with NZ IFRS (New Zealand equivalents to International Financial Reporting Standards) and are not uniformly defined; therefore, the non-GAAP profit measures included in this report are not comparable with those used by other companies. They should not be viewed in isolation or as a substitute for GAAP profit measures as reported by Sanford in accordance with NZ IFRS.

Definitions

EBIT: Earnings before interest and taxation.

Adjusted EBIT: Earnings before interest, taxation, restructuring costs, impairment of assets and investments, gain on sale from transactions, net loss on sale of property, plant and equipment, and intangible assets and other one-off items.

Adjusted EBITDA: Adjusted EBIT before depreciation and amortisation.

Consolidated Condensed Interim Financial Statements

For the six months ended 31 March 2025

Consolidated Condensed 7 Income Statement 8 Consolidated Condensed Statement of Comprehensive Income Consolidated Condensed Statement of Financial Position Consolidated Condensed Statement of Cash Flows Consolidated Condensed Statement 10 of Cash Flows Consolidated Condensed Statement 12 of Changes in Equity Notes to the Consolidated 14 Condensed Interim Financial Statements

Consolidated Condensed Income Statement

for the six months ended 31 March 2025

| for the six months ended 51 March 2025 | | | | |
|---|------|--|--|---|
| | | Unaudited 6 months ended 31 March 2025 | Unaudited 6 months ended 31 March 2024 | Audited 12 months ended 30 September 2024 |
| | Note | \$000 | \$000 | \$000 |
| Revenue | 3 | 285,999 | 275,978 | 582,913 |
| Cost of sales | | (205,463) | (207,350) | (456,726) |
| Gross profit | | 80,536 | 68,628 | 126,187 |
| Other income | 7 | 3,480 | 3,490 | 7,240 |
| Distribution expenses | | (6,236) | (6,515) | (13,630) |
| Administrative expenses | | (16,273) | (19,464) | (33,778) |
| Other expenses | 8 | (7,058) | (10,979) | (31,896) |
| Operating profit | | 54,449 | 35,160 | 54,123 |
| | | | | |
| Finance income | | 820 | 605 | 1,270 |
| Finance expense | | (7,726) | (9,805) | (18,137) |
| Net finance expense | | (6,906) | (9,200) | (16,867) |
| | | | | |
| Share of profit of equity-accounted investees | | 8 | 27 | 139 |
| Profit before income tax | | 47,551 | 25,987 | 37,395 |
| Income tax expense | | (13,518) | (9,833) | (17,725) |
| Profit for the period | | 34,033 | 16,154 | 19,670 |
| Profit attributable to: | | | | |
| Equity holders of the Company | | 34,034 | 16,166 | 19,685 |
| Non-controlling interest | | (1) | (12) | (15) |
| | | 34,033 | 16,154 | 19,670 |
| Earnings per share attributable to equity holders of the Company during the period (expressed in cents per share) | | | | |
| Basic and diluted earnings per share (cents) | | 36.4 | 17.3 | 21.1 |

Consolidated Condensed Statement of Comprehensive Income for the six months ended 31 March 2025

| for the six months ended 31 March 2025 | Unaudited 6 months ended 31 March 2025 | Unaudited 6 months ended 31 March 2024 | Audited 12 months ended 30 September 2024 |
|---|--|--|---|
| | \$000 | \$000 | \$000 |
| Profit for the period (after tax) | 34,033 | 16,154 | 19,670 |
| Other comprehensive income | | | |
| Items that may be reclassified to the income statement: | | | |
| Foreign currency translation differences | 43 | 70 | 68 |
| Change in fair value of cash flow hedges recognised in other comprehensive income | (32,193) | (1,239) | 14,119 |
| Deferred tax on cash flow hedges | 9,014 | 347 | (3,953) |
| Items that have been classified to the income statement: | | | |
| Amount of treasury share cost expensed in relation to share-based payment | 375 | _ | _ |
| Cost of hedging gain | _ | (293) | (293) |
| Deferred tax on cost of hedging | _ | 82 | 82 |
| Other comprehensive (loss)/income for the period | (22,761) | (1,033) | 10,023 |
| Total comprehensive income for the period | 11,272 | 15,121 | 29,693 |
| Total comprehensive income for the period is attributable to: | | | |
| Equity holders of the Company | 11,273 | 15,133 | 29,708 |
| Non-controlling interest | (1) | (12) | (15) |
| Total comprehensive income for the period | 11,272 | 15,121 | 29,693 |

Consolidated Condensed Statement of Financial Position

| as at 31 March 2025 | | | | |
|-----------------------------------|------|--|--|---|
| | | Unaudited 6 months ended 31 March 2025 | Unaudited 6 months ended 31 March 2024 | Audited 12 months ended 30 September 2024 |
| | Note | \$000 | \$000 | \$000 |
| Current assets | | | | |
| Cash on hand and at bank | 6 | 11,901 | 6,547 | 14,475 |
| Trade receivables | 6 | 92,865 | 102,948 | 83,167 |
| Derivative financial instruments | | 1,307 | 4,051 | 13,556 |
| Other receivables and prepayments | | 10,236 | 7,367 | 5,085 |
| Biological assets | | 66,328 | 57,730 | 55,557 |
| Inventories | | 84,607 | 90,548 | 73,363 |
| Assets held for sale | 9 | 19,616 | 12,807 | 19,706 |
| Total current assets | | 286,860 | 281,998 | 264,909 |
| Non-current assets | | | | |
| Property, plant and equipment | | 219,220 | 235,568 | 217,819 |
| Right-of-use assets | | 33,319 | 37,993 | 32,751 |
| Investments | | 578 | 1,148 | 1,261 |
| Derivative financial instruments | | 1,698 | 10,721 | 16,364 |
| Biological assets | | 15,790 | 15,239 | 23,239 |
| Intangible assets | | 489,561 | 491,848 | 490,087 |
| Total non-current assets | | 760,166 | 792,517 | 781,521 |
| Total assets | | 1,047,026 | 1,074,515 | 1,046,430 |
| Current liabilities | | | | |
| Derivative financial instruments | | 8,045 | 4,417 | 1,705 |
| Trade and other payables | | 53,007 | 61,106 | 44,647 |
| Taxation payable | | 6,497 | 841 | 899 |
| Lease obligations | | 5,615 | 13,648 | 13,889 |
| Liabilities held for sale | 9 | 14,024 | 13,326 | 12,908 |
| Total current liabilities | | 87,188 | 93,338 | 74,048 |
| Non-current liabilities | | | | |
| Bank loans (secured) | 4 | 177,000 | 227,000 | 200,000 |
| Contributions received in advance | | 1,379 | 1,703 | 1,531 |
| Employee entitlements | | 1,139 | 1,233 | 1,260 |
| Derivative financial instruments | | 4,013 | 775 | 1,145 |
| Deferred taxation | | 40,573 | 34,287 | 43,646 |
| Lease obligations | | 24,873 | 21,717 | 20,442 |
| Total non-current liabilities | | 248,977 | 286,715 | 268,024 |
| Total liabilities | | 336,165 | 380,053 | 342,072 |
| Equity | | | | |
| Paid in capital | | 94,690 | 94,690 | 94,690 |
| Retained earnings | | 619,680 | 591,572 | 590,415 |
| Other reserves | | (3,873) | 7,832 | 18,888 |
| Shareholder funds | | 710,497 | 694,094 | 703,993 |
| Non-controlling interest | | 364 | 368 | 365 |
| Total equity | | 710,861 | 694,462 | 704,358 |
| Total equity and liabilities | | 1,047,026 | 1,074,515 | 1,046,430 |

Consolidated Condensed Statement of Cash Flows

for the six months ended 31 March 2025

| for the six months ended 31 March 2025 | | | |
|--|--|--|---|
| | Unaudited 6 months ended 31 March 2025 | Unaudited 6 months ended 31 March 2024 | Audited 12 months ended 30 September 2024 |
| Note | \$000 | \$000 | \$000 |
| Cash flows from operating activities | | | |
| Receipts from customers | 308,756 | 290,031 | 630,832 |
| Interest received | 820 | 604 | 1,270 |
| Payments to suppliers and employees | (250,901) | (269,813) | (533,856) |
| Income tax paid | (1,977) | (4,768) | (7,770) |
| Interest paid | (7,076) | (7,804) | (17,480) |
| Net cash flows from operating activities | 49,622 | 8,250 | 72,996 |
| Cash flows from investing activities | | | |
| Proceeds from sale of North Island Mussels Limited | | | |
| assets 9(b) | 2,695 | - | _ |
| Proceeds from sale of property, plant and equipment | 24 | 12 | 1,306 |
| Proceeds from sale of North Island inshore | | | |
| fishery assets 7 | _ | 6,830 | 6,830 |
| Proceeds from sale of investment in Two Islands NZ Co Limited 8 | _ | _ | 200 |
| Dividends received from associates | 690 | 383 | 383 |
| Purchase of property, plant and equipment | (15,790) | (22,504) | (45,916) |
| Purchase of intangible assets | (380) | (684) | (1,490) |
| Acquisition of shares in other companies | _ | (278) | (278) |
| Net cash flows from investing activities | (12,761) | (16,241) | (38,965) |
| Cash flows from financing activities | | | |
| Proceeds from borrowings 4 | _ | 24,000 | 27,000 |
| Repayment of term loans 4 | (23,000) | _ | (30,000) |
| Lease payments | (11,668) | (10,693) | (13,135) |
| Dividends paid to Company shareholders 5 | , | (5,610) | (10,286) |
| Net cash flows from financing activities | (39,437) | 7,697 | (26,421) |
| Not (degrees) linerage in each and | | | |
| Net (decrease)/increase in cash and cash equivalents | (2,576) | (294) | 7,610 |
| Effect of exchange rate fluctuations on cash held | 2 | 36 | 60 |
| Cash and cash equivalents at beginning of the period | 14,475 | (51,195) | (51,195) |
| Short-term borrowings reclassified as term loans | _ | 58,000 | 58,000 |
| Cash and cash equivalents at end of the period | 11,901 | 6,547 | 14,475 |
| Represented by: | | | |
| Cash on hand and at bank | 11,901 | 6,547 | 14,475 |
| | 11,901 | 6,547 | 14,475 |

Consolidated Condensed Statement of Cash Flows for the six months ended 31 March 2025

Reconciliation of Profit for the Period with Net Cash Flows from Operating Activities

| | | Unaudited 6 months ended 31 March 2025 | Unaudited 6 months ended 31 March 2024 | Audited 12 months ended 30 September 2024 |
|---|------|--|--|---|
| | Note | \$000 | \$000 | \$000 |
| Profit for the period (after tax) | | 34,033 | 16,154 | 19,670 |
| Adjustments for non-cash items | | | | |
| Depreciation and amortisation | | 17,393 | 17,542 | 34,442 |
| Depreciation – Annual Catching Entitlement (ACE) | | 4,257 | 3,873 | 7,746 |
| Impairment of investment | 8 | _ | 3,333 | 2,956 |
| Impairment of property, plant and equipment | 8 | 115 | _ | 14,837 |
| Impairment of intangibles | 8 | _ | - | 1,832 |
| Share-based payment expense | | 375 | - | _ |
| Change in fair value of biological assets | | (3,322) | (6,443) | (12,270) |
| Change in fair value of forward exchange contracts and foreign currency options | | 3,918 | (851) | (2,882) |
| Unrealised foreign exchange (gains)/losses | | (4,888) | (1,425) | 1,489 |
| Share of profit of equity accounted investees | | (8) | (27) | (139) |
| Increase in deferred tax liability | | 5,941 | 7,720 | 12,697 |
| Decrease in contributions received in advance | | (152) | (175) | (347) |
| Other | | _ | (7) | 187 |
| | | 23,629 | 23,540 | 60,548 |
| Movements in working capital | | | | |
| (Increase)/decrease in trade and other receivables | | | | |
| and prepayments | | (9,302) | 4,186 | 23,410 |
| (Increase)/decrease in inventories | | (11,242) | (7,505) | 9,666 |
| Increase/(decrease) in trade and other payables and other liabilities | | 7,765 | (24,366) | (40,446) |
| Increase/(decrease) in taxation payable | | 5,598 | (2,801) | (2,726) |
| mercuse/(decrease/ in taxation payable | | (7,181) | (30,486) | (10,096) |
| Items classified as investing activities | | | | |
| Net loss on sale of property, plant and equipment | | 181 | 6 | 3,838 |
| Gain on sale of North Island Mussels Limited assets | 7 | (1,040) | 0 | 3,030 |
| Net gain on sale of North Island inshore fishery assets | 7 | (1,040) | (964) | (964) |
| The gain on sale of the threshold mention field y deserts | , | (859) | (958) | 2,874 |
| Net cash flows from operating activities | | 49,622 | 8,250 | 72,996 |

Consolidated Condensed Statement of Changes in Equity for the six months ended 31 March 2025

| for the six months ended 31 March 2025 | | Share Capital | Share-based Payment Reserve | Translation Reserve | Cash Flow Hedge Reserve | Cost of Hedging Reserve | Retained Earnings | Total | Non-controlling Interest | Total Equity |
|---|------|------------------|--------------------------------|------------------------|----------------------------|----------------------------|----------------------|----------|-----------------------------|-----------------|
| | Note | \$000 | \$000 | \$000 | \$000 | \$000 | \$000 | \$000 | \$000 | \$000 |
| Balance at 01 October 2024 (audited) | | 94,690 | _ | 1,153 | 17,735 | _ | 590,415 | 703,993 | 365 | 704,358 |
| Profit for the period (after tax) | | _ | _ | _ | - | _ | 34,034 | 34,034 | (1) | 34,033 |
| Other comprehensive income | | | | | | | | | | |
| Foreign currency translation differences | | _ | _ | 43 | - | _ | _ | 43 | _ | 43 |
| Hedging losses recognised in other comprehensive income | | - | _ | - | (32,193) | _ | _ | (32,193) | - | (32,193) |
| Deferred tax on change in reserves | | _ | _ | - | 9,014 | _ | _ | 9,014 | _ | 9,014 |
| Amount of treasury share cost expensed in relation to share-based payment | | - | 375 | _ | _ | _ | _ | 375 | _ | 375 |
| Total comprehensive income | | | 375 | 43 | (23,179) | _ | 34,034 | 11,273 | (1) | 11,272 |
| Distributions to shareholders | 5 | _ | _ | _ | _ | _ | (4,769) | (4,769) | _ | (4,769) |
| Balance at 31 March 2025 (unaudited) | | 94,690 | 375 | 1,196 | (5,444) | _ | 619,680 | 710,497 | 364 | 710,861 |
| | | | | | | | | | | |
| Balance at 01 October 2023 (audited) | - | 94,690 | _ | 1,085 | 7,569 | 211 | 581,016 | 684,571 | 380 | 684,951 |
| Profit for the period (after tax) | | _ | _ | _ | _ | _ | 16,166 | 16,166 | (12) | 16,154 |
| Other comprehensive income | | _ | _ | _ | _ | _ | _ | | _ | |
| Foreign currency translation differences | | _ | _ | 70 | _ | _ | _ | 70 | _ | 70 |
| Hedging losses recognised in other comprehensive income | | _ | _ | _ | (1,239) | _ | _ | (1,239) | _ | (1,239) |
| Deferred tax on change in reserves | | _ | _ | _ | 347 | _ | _ | 347 | _ | 347 |
| Cost of hedging gains recovered to the income statement | | _ | _ | _ | _ | (293) | _ | (293) | _ | (293) |
| Deferred tax on cost of hedging | | _ | _ | _ | _ | 82 | _ | 82 | _ | 82 |
| Total comprehensive income | | _ | _ | 70 | (892) | (211) | 16,166 | 15,133 | (12) | 15,121 |
| Distributions to shareholders | 5 | _ | _ | _ | _ | _ | (5,610) | (5,610) | _ | (5,610) |
| Balance at 31 March 2024 (unaudited) | | 94,690 | _ | 1,155 | 6,677 | _ | 591,572 | 694,094 | 368 | 694,462 |
| | | | | | | | | | | |
| Balance at 01 October 2023 (audited) | - | 94,690 | _ | 1,085 | 7,569 | 211 | 581,016 | 684,571 | 380 | 684,951 |
| Profit for the period (after tax) | | _ | _ | _ | - | _ | 19,685 | 19,685 | (15) | 19,670 |
| Other comprehensive income | | _ | _ | | | | | | | |
| Foreign currency translation differences | | _ | _ | 68 | - | _ | _ | 68 | _ | 68 |
| Hedging gains recognised in other comprehensive income | | - | _ | _ | 14,119 | _ | _ | 14,119 | - | 14,119 |
| Deferred tax on change in reserves | | _ | _ | _ | (3,953) | _ | _ | (3,953) | _ | (3,953) |
| Cost of hedging gains recovered to the income statement | | _ | _ | _ | _ | (293) | _ | (293) | _ | (293) |
| Deferred tax on cost of hedging | | _ | _ | _ | _ | 82 | _ | 82 | _ | 82 |
| Total comprehensive income | - | _ | _ | 68 | 10,166 | (211) | 19,685 | 29,708 | (15) | 29,693 |
| Distributions to shareholders | 5 | - | _ | _ | | - | (10,286) | (10,286) | _ | (10,286) |
| Balance at 30 September 2024 (audited) | - | 94,690 | _ | 1,153 | 17,735 | _ | 590,415 | 703,993 | 365 | 704,358 |

for the six months ended 31 March 2025

Note 1 - General Information

Sanford Limited is a profit-orientated company that is domiciled and incorporated in New Zealand. The Company is registered under the Companies Act 1993 and listed on the New Zealand Stock Exchange (NZX). The Company is an FMC entity for the purposes of Part 7 of the Financial Markets Conduct Act 2013.

The unaudited financial statements presented are for Sanford Limited ('Sanford', the 'Company' or the 'Group') as at and for the six months ended 31 March 2025. The Group comprises Sanford Limited, its subsidiaries and its investments in joint arrangements and associates.

The interim financial statements are prepared in accordance with NZ IAS 34: Interim Financial Reporting. The interim financial statements and the comparative information for the six months ended 31 March 2024 are unaudited. The comparative information for the year ended 30 September 2024 is audited.

The Group is a large and long-established fishing and aquaculture farming business devoted entirely to the farming, harvesting, processing, storage and marketing of quality seafood products and investments in related activities.

The Group's key operating business units are:

- Wildcatch responsible for catching and processing deepwater fish species, and the leasing of Annual Catch Entitlements (ACE) for North Island inshore species; and
- Aquaculture responsible for farming, harvesting and processing mussels and salmon.

Note 2 - Basis of Preparation

Significant accounting policies

The Group's accounting policies have been applied consistently to all periods presented in these interim financial statements, and have been applied consistently by Group entities. The interim financial statements should be read in conjunction with the financial statements for the year ended 30 September 2024.

New and amended accounting standards and interpretations adopted

Amendment to NZ IAS 1: Presentation of Financial Statements, Classification of Liabilities as Current or Non-current

The Amendment to NZ IAS 1: Presentation of Financial Statements, Classification of Liabilities as Current or Non-current (the Amendment) is effective for the Group in the financial year ended 30 September 2025. Under the Amendment, an entity classifies a liability as current unless the entity has a right to defer settlement of the liability for at least 12 months after the reporting period. The right must also exist at the reporting date and have substance. The Group elected to early adopt the Amendment, effective from 01 October 2023. Bank loans drawn under the Group's working capital facilities were classified as non-current liabilities at 31 March 2024 and 30 September 2024 as a result. Refer to note 4 for details on bank loans.

Note 3 — Segment Reporting

Sanford's management monitors the operating results of the Wildcatch and Aquaculture (mussels and salmon) business units. Business unit performance is evaluated based on operating profit or loss. Capital expenditure consists of additions of property, plant and equipment and intangible assets.

The Group has determined that the business units should be aggregated to form one reportable segment to reflect the farming, harvesting, processing and selling of seafood products, due to the aggregated manner in which performance is monitored. Further information on segment reporting is included in the financial statements for the year ended 30 September 2024.

Note 3 — Segment Reporting (continued)

Revenue by geographical location of customers

| | Unaudited 6 months ended 31 March 2025 | Unaudited 6 months ended 31 March 2024 | Audited 12 months ended 30 September 2024 |
|---------------------------|--|--|---|
| | \$000 | \$000 | \$000 |
| New Zealand | 106,189 | 104,318 | 222,699 |
| North America | 57,416 | 60,977 | 125,188 |
| Europe | 42,287 | 24,117 | 66,183 |
| China | 31,640 | 37,399 | 78,573 |
| Australia | 22,425 | 24,871 | 43,631 |
| Other Asia | 6,741 | 8,532 | 19,019 |
| Middle East | 6,416 | 1,286 | 4,000 |
| Japan | 4,675 | 5,774 | 10,516 |
| South Korea | 3,883 | 3,042 | 5,493 |
| Hong Kong | 1,739 | 1,365 | 2,882 |
| Africa | 1,441 | 329 | 764 |
| Pacific | 960 | 2,374 | 2,117 |
| Central and South America | 187 | 1,594 | 1,848 |
| Revenue | 285,999 | 275,978 | 582,913 |

The revenue information above is based on the delivery destination of sales.

The Group has one customer accounting for more than 10% of total sales for the current period across both Wildcatch and Aquaculture (six months ended 31 March 2024: one customer; year ended 30 September 2024: Nil).

Note 4 - Bank Loans (Secured)

| | C | Carrying and face value | | | | |
|------------------------------------|----------------------------|----------------------------|------------------------------|--|--|--|
| | Unaudited 31 March 2025 | Unaudited 31 March 2024 | Audited 30 September 2024 | | | |
| | \$000 | \$000 | \$000 | | | |
| Balance at beginning of the period | 200,000 | 203,000 | 203,000 | | | |
| Bank term loans | | | | | | |
| Proceeds | _ | 24,000 | 27,000 | | | |
| Repayments | (23,000) | _ | (30,000) | | | |
| Balance at end of the period | 177,000 | 227,000 | 200,000 | | | |
| Interest rates applicable | 4.3% – 5.1% | 6.2% - 6.8% | 5.6% - 6.7% | | | |

All syndicated bank loans are secured by a general security interest over property and a mortgage over all quota shares. All borrowings are subject to borrowing covenant arrangements, which include interest cover ratio, gearing ratio and ratios of assets and EBITDA between Sanford and the Guaranteeing Group. The Group has complied with all covenants during the period (March 2024: all covenants were complied with; September 2024: all covenants were complied with).

Interest rates for all loans are floating based on the bank bill rate plus a margin. The Group's policy for term loans is to hedge between 25% and 75% of floating rate debt by using interest rate swaps.

for the six months ended 31 March 2025

Note 4 - Bank Loans (Secured) (continued)

Refinancing activities and loan balances

The Group completed refinancing activities on 31 January 2025. Expiry dates for the Group's banking facilities were extended, and the total facility limit was reduced from \$250m as at 30 September 2024 to \$230m.

Banking facilities, expiry dates and balances of bank loans for the Group are illustrated in the table below.

| Non-current facilities | Unaudited | | | | |
|-----------------------------------|---------------------|-------------------------|---------|--|--|
| Syndicated and secured bank loans | As at 31 March 2025 | | | | |
| | Facility | Expiry Date | Balance | | |
| | \$000 | | \$000 | | |
| | 85,000 | April 2026 – April 2027 | 66,000 | | |
| | 125,000 | April 2028 | 100,000 | | |
| | 20,000 | April 2029 | 11,000 | | |
| | 230,000 | | 177,000 | | |

| Non-current facilities | | Audited | | | Unaudited | | |
|-----------------------------------|----------|-------------------------|---------|----------|-------------------------|---------|--|
| Syndicated and secured bank loans | | As at 30 September 2024 | | | As at 31 March 2024 | | |
| | Facility | Expiry Date | Balance | Facility | Expiry Date | Balance | |
| | \$000 | | \$000 | \$000 | | \$000 | |
| | 40,000 | November 2025 | 30,000 | 60,000 | April/November 2025 | 60,000 | |
| | 85,000 | March 2026 - April 2026 | 85,000 | 85,000 | March 2026 - April 2026 | 82,000 | |
| | 95,000 | April 2026 | 55,000 | 75,000 | April 2026 | 55,000 | |
| | 30,000 | April 2028 | 30,000 | 30,000 | April 2028 | 30,000 | |
| | 250,000 | | 200,000 | 250,000 | | 227,000 | |

Note 5 — Dividends

The following dividends were declared and paid by the Company:

On 14 May 2025 the Board declared an interim dividend for the six months ended 31 March 2025 of 5.0 cents per share (31 March 2024: 5.0 cents per share; 30 September 2024: a final dividend of 5.0 cents per share was approved by the Board on 14 November 2024 and paid on 9 December 2024).

Note 6 - Financial Instruments

Carrying amounts and fair values

The following table shows the carrying amounts and fair values of financial assets and financial liabilities at reporting date.

| | | Unaudited 6 months ended 31 March 2025 | Unaudited 6 months ended 31 March 2024 | Audited 12 months ended 30 September 2024 |
|---|------|--|--|---|
| | Note | \$000 | \$000 | \$000 |
| Non-derivative financial assets not measured at fair value ⁽ⁱ⁾ | | | | |
| Trade receivables | | 92,865 | 102,948 | 83,167 |
| Cash and cash equivalents | | 11,901 | 6,547 | 14,475 |
| Other receivables – advances to associates | | 137 | 137 | 137 |
| Shares in other companies | | 104 | 104 | 104 |
| Non-derivative financial liabilities not measured at fair value (1) | | | | |
| Trade and other payables | | (44,649) | (52,539) | (36,227) |
| Bank term loans (secured) | 4 | (177,000) | (227,000) | (200,000) |
| Total net non-derivative financial liabilities | | (116,642) | (169,803) | (138,344) |
| Derivative financial (liabilities)/assets measured at fair value (III) | | | | |
| Forward exchange contracts | | (8,400) | 5,335 | 28,689 |
| Interest rate swaps | | 105 | 3,476 | 314 |
| Fuel swaps | | (758) | 769 | (1,933) |
| Total net derivative financial (liabilities)/assets | | (9,053) | 9,580 | 27,070 |

⁽i) Presented at carrying value that is equivalent to fair value.

Other payables that are not financial liabilities are excluded above (provisions and employee entitlements: March 2025: \$8.4m; March 2024: \$8.6m; September 2024: \$8.4m).

Note 7 - Other Income

31 March 2025 - Gain on sale of North Island Mussels Limited assets

Included in other income is a gain on sale of \$1.0m from the sale of North Island Mussels Limited assets that were classified as assets held for sale at 30 September 2024. Refer to note 9 (b) for details.

$31\,March\,2024\,and\,30\,September\,2024-Net\,gain\,on\,sale\,of\,North\,Island\,inshore\,fishery\,assets$

On 31 October 2023 the agreement for Sanford to lease the Annual Catch Entitlement (ACE) for much of its quota of North Island inshore species to Aotearoa Fisheries Limited (Moana) on a long-term basis became unconditional. The transaction included the sale of two of the Group's inshore fishing vessels, a selection of processing equipment, refrigerated vehicles/trailers, and one marine farm comprising three coastal permits in the Croisilles Harbour. The assets and marine farm licences were classified as assets held for sale (net of impairment) at 30 September 2023. In the six months ended 31 March 2024 and the year ended 30 September 2024, the Group received total consideration of \$6.8m for the assets, resulting in a gain on sale of \$0.96m which is included in other income in the income statement of the comparatives.

⁽ii) Presented at fair value.

for the six months ended 31 March 2025

Note 8 — Other Expenses

Material items included in other expenses in the comparative income statements are listed in the table below.

| | | Unaudited 6 months ended 31 March 2024 | Audited 12 months ended 30 September 2024 |
|--|----------|--|---|
| | Note | \$000 | \$000 |
| Impairment of investment and advances in Two Islands Co NZ Limited | i | 3,333 | 2,956 |
| Impairment of property, plant and equipment | 9(a)/(b) | _ | 14,837 |
| Impairment of intangible assets | ii | _ | 1,832 |

There were no material impairments in the six months ended 31 March 2025.

- i. In the six months ended 31 March 2024 the Group impaired its equity accounted investment in Two Islands Co NZ Limited, including its subsidiary Two Islands Co Australia Pty Limited, by \$2.9m. An advance to Two Islands Co NZ Limited of \$0.2m including interest was also written off. Subsequent to 31 March 2024 the impaired investment was sold for a consideration of \$0.2m.
- ii. Included in the impairment of intangible assets for the year ended 30 September 2024 was an impairment of goodwill balance of \$1.4m associated with Enzaq, a mussel powder business acquired in 2017.

Note 9 - Assets held for sale

(a) Auckland site sale of perpetual right to lease land and building assets

31 March 2025

In the six months ended 31 March 2025 a conditional sale and purchase agreement was signed to sell the Auckland site's perpetual right to lease the land and buildings. This did not give rise to any accounting as the fair value adjustment and related impairment were recognised in the year ended 30 September 2024, noted below. The assets and lease obligation are disclosed as held for sale due to the conditional nature of the contract.

31 March 2024 and 30 September 2024

The perpetual right to lease the Auckland premises was classified as held for sale at 31 March 2024. As at 30 September 2024, the signing of a sale and purchase contract was considered imminent. On this basis these site leases and associated buildings were classified as held for sale.

At 30 September 2024 the conditional contract with the developer provided evidence of the fair value of the lease and building assets, which overall indicated there would be a gain from this transaction to be recognised if the conditions of the contract are fulfilled in the future. The conditional contract at this time provided evidence as to the fair value of the building assets prior to its reclassification to assets held for sale, which was less than the carrying value. In light of this the buildings were impaired by \$4.2m as at 30 September 2024.

| | Unaudited 31 March 2025 | Unaudited 31 March 2024 | Audited 30 September 2024 |
|-------------------------------------|----------------------------|----------------------------|------------------------------|
| | \$000 | \$000 | \$000 |
| Assets | | | |
| Right-of-use assets | 14,373 | 12,807 | 12,807 |
| Buildings | 5,243 | _ | 5,243 |
| Total | 19,616 | 12,807 | 18,050 |
| Liabilities Lease obligation | (14,024) | (13,326) | (12,908) |
| Net held for sale asset position | 5,592 | (519) | 5,142 |

Note 9 - Assets held for sale (continued)

(b) Closure of North Island Mussels Limited mussels processing facility

North Island Mussels Limited (NIML) is a joint operation in which Sanford Limited has 50% shareholding to farm, process and sell mussels. The processing plant, based in Tauranga, was closed in the year ended 30 September 2024. Land, buildings, plant and equipment of the Tauranga site were actively marketed for sale in 2024 and as such were classified as held for sale at 30 September 2024. Total book value of assets held for sale less impairment was \$1.7m. Sanford's share of impairment was \$6.4m as recognised in the income statement in FY24.

The sale was completed in the six months ended 31 March 2025 for a consideration of \$2.7m, resulting in a gain on sale of \$1.0m, which is included in other income in the income statement.

As this is a joint operation, the Group recognises its share of NIML's assets, liabilities, revenues and expenses. The numbers presented are therefore representative of the Group's 50% share only.

| | Audited 30 September 2024 |
|----------------------------------|------------------------------|
| | \$000 |
| Assets | |
| Land | 880 |
| Buildings | 776 |
| Net held for sale asset position | 1,656 |

Note 10 - Assets Valuation

Other than that noted in note 8, there have been no other material impairment losses recognised in the six months ended 31 March 2025 or 31 March 2024, or in the year ended 30 September 2024.

Impairment testing

The Group's market capitalisation has been below the carrying amount of net assets from September 2020. At 31 March 2025 the Group's market capitalisation was \$473m (31 March 2024: \$383m; 30 September 2024: \$353m) and the carrying value of its net assets was \$711m (31 March 2024: \$694m; 30 September 2024: \$704m). Accounting standards consider this to be an indicator of impairment

Management undertakes impairment testing annually in respect of the cash-generating units (CGU) that contain the New Zealand fishing quota and marine farm licences using the value-in-use methodology. When the carrying value of an asset exceeds its recoverable amount, the asset is considered impaired and is written down to its recoverable amount. The recoverable amount is the greater of fair value less cost to sell and its value-in-use.

This testing results in positive headroom between the value of these CGUs and the carrying amount of their net assets, indicating that there is no impairment at the CGU level.

The recoverable amounts of the CGUs were estimated based on the following significant assumptions:

- Post tax discount rates of 8.1% to 9.1% were applied, the midpoint being 8.6% (31 March 2024: 8.5%; 30 September 2024: 8.5%)
- Future cashflows were projected for a period of five years and a terminal growth rate of 2.25% (31 March 2024: 2.25%; 30 September 2024: 2.25%)
- The Aquaculture CGU assumes that for the FY25–FY29 (31 March 2024: FY24–FY28, 30 September 2024: FY25–FY29) period the compound annual growth rate (CAGR) of earnings is 1.6% (31 March 2024: 10.8%; 30 September 2024: 10.2%) and for the equivalent period for the New Zealand Wildcatch CGU the CAGR of earnings is 22.3% (31 March 2024: 3.9%; 30 September 2024: 24.8%).

The recoverable amount of New Zealand Wildcatch exceeds its carrying amount by \$99m (31 March 2024: \$137m; 30 September 2024: \$109m) and Aquaculture by \$137m (31 March 2024: \$80m; 30 September 2024: \$93m).

Sensitivity analysis

The Group has conducted an analysis of the sensitivity of the impairment test to changes in key assumptions used to determine the recoverable amounts for the applicable CGUs. The recoverable amounts in the New Zealand Wildcatch and Aquaculture CGUs are not sensitive to reasonably possible changes in assumptions of the Group's terminal growth and discount rates. However, the recoverable amounts are sensitive to reasonably possible changes in assumptions of the Group's earnings growth expectations.

For the Aquaculture CGU, if the earnings assumption was assumed to have a CAGR of -10.4% (31 March 2024: no growth through to FY28; 30 September 2024: 1.2% through to FY29), then the carrying amount would approximately equal the recoverable amount.

For the New Zealand Wildcatch CGU, earnings would have to fall to a CAGR of 16.6% (31 March 2024: 4.9%; 30 September 2024: 18.4%) over the modelled period for the carrying amount to equal the recoverable amount.

for the six months ended 31 March 2025

Note 11 - Contingent Liabilities and Commitments

(a) Contingent liabilities

| | Unaudited 31 March 2025 | Unaudited 31 March 2024 | Audited 30 September 2024 |
|------------|----------------------------|----------------------------|------------------------------|
| | \$000 | \$000 | \$000 |
| Guarantees | 801 | 801 | 801 |

The Group has guarantees with its commercial banking partners. In this respect the Group treats the guarantee contracts as contingent liabilities until such times as it becomes probable that the Group will be required to make payments under the guarantees.

(b) Commitments

The estimated capital expenditure for property, plant and equipment contracted for at reporting date but not provided is \$7.4m (31 March 2024: \$16.2m; 30 September 2024: \$4.4m).

Note 12 - Subsequent Events

Interim dividend approval

The Board approved an interim dividend for the six months ended 31 March 2025 on 14 May 2025. Refer to note 5 for details.

Directory

Board of Directors

Sir Robert McLeod, Chair KNZM, LLB/BCom, FCA

David Mair BE (Civil), MBA

Tom McClurg B.Ag.Sc, RLV, M.Sc.

(Natural Resource Management)

Joanne Curin BCom, FCA

Craig Ellison

M.Sc. (Zoology)

John Strowger LLB (Hons)

Officers

David Mair, Managing Director Paul Alston, Chief Financial Officer Vaughan Wilkinson, Strategy and Innovation Officer Debra Lumsden, Chief People Officer

Registered Office

22 Jellicoe Street Freemans Bay Auckland 1010 New Zealand

PO Box 443 Shortland Street Auckland 1140 New Zealand

Website: sanford.co.nz

Principal Bankers

ANZ Bank New Zealand Limited Bank of New Zealand Rabobank New Zealand Limited

Solicitors

Chapman Tripp Russell McVeagh

Group Auditor

KPMG, Auckland

Stock Exchange

The Company's shares trade on the New Zealand Stock Exchange (NZX).

NZX Trading Code: SAN

Share Registrar

Computershare Investor Services Limited Private Bag 92 119 Victoria Street West Auckland 1142 New Zealand

159 Hurstmere Road Takapuna Auckland 0622 New Zealand

Managing your Shareholding

Online: investorcentre.com/nz

To change your address, update your payment instructions and to view your investment portfolio including transactions.

Email: enquiry@computershare.co.nz

Please assist our registrar by quoting your CSN or shareholder number.

